Answers are grounded in this paper and cite their sources.
B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T-cell therapies induce high response rates in relapsed or refractory multiple myeloma but have been associated with distinct neurotoxicity profiles. The mechanisms underlying these events remain incompletely understood. Here, we describe a novel tandem BCMA-specific CAR T construct, LTG3551, with reduced antigen-independent activation. LTG3551 demonstrated potent and sustained anti-myeloma activity compared to cilta-cel-like and ide-cel-like CAR T-cells in vitro with enhanced expansion and lower cytokine levels in the MM.1S xenograft myeloma model. Cilta-cel-like CAR T-cells exhibited increased tonic signaling characterized by spontaneous cytokine secretion, metabolic activity, and antigen-independent cytotoxicity when cultured with human microglial cells in vitro . These features were attenuated in LTG3551. Taken together, these findings suggest the biological effects of tonic CAR signaling are associated with off-tumor toxicity and support investigation of LTG3551 as a BCMA CAR T-cell therapy with an improved safety profile.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.